Current
$39.6B
5-Year Average
$30.4B
All-Time High
$65B
All-Time Low
$7.37M
Market cap daily chart for Alnylam Pharmaceuticals (ALNY)
Aug 2, 2021 – Jul 29, 2026 · 1,253 trading days
Market Cap growth chart for Alnylam Pharmaceuticals (ALNY) from 2017 to 2026
Latest: -26.0%
Market Cap history table for Alnylam Pharmaceuticals (ALNY) from 2004 to 2026
| 2026 | $39.6B | -26.0% | -$13.9B | ||
| 2025 | $53.6B | +78.3% | +$23.5B | ||
| 2024 | $30B | +25.6% | +$6.13B | ||
| 2023 | $23.9B | -17.3% | -$5.01B | ||
| 2022 | $28.9B | +44.0% | +$8.83B | ||
| 2021 | $20.1B | +34.4% | +$5.14B | ||
| 2020 | $14.9B | +18.8% | +$2.36B | ||
| 2019 | $12.6B | +71.6% | +$5.25B | ||
| 2018 | $7.33B | -36.3% | -$4.17B | ||
| 2017 | $11.5B | +259.0% | +$8.3B | ||
| 2016 | $3.2B | -59.5% | -$4.7B | ||
| 2015 | $7.91B | +9.7% | +$702M | ||
| 2014 | $7.2B | +82.0% | +$3.25B | ||
| 2013 | $3.96B | +331.3% | +$3.04B | ||
| 2012 | $918M | +165.5% | +$572M | ||
| 2011 | $346M | -16.6% | -$68.9M | ||
| 2010 | $415M | -43.5% | -$319M | ||
| 2009 | $734M | -27.8% | -$282M | ||
| 2008 | $1.02B | -9.6% | -$108M | ||
| 2007 | $1.12B | +64.7% | +$442M | ||
| 2006 | $682M | +132.7% | +$389M | ||
| 2005 | $293M | +230.3% | +$204M | ||
| 2004 | $88.8M | — | — |
- 2026$39.6B-26.0%
- 2025$53.6B+78.3%
- 2024$30B+25.6%
- 2023$23.9B-17.3%
- 2022$28.9B+44.0%
- 2021$20.1B+34.4%
- 2020$14.9B+18.8%
- 2019$12.6B+71.6%
- 2018$7.33B-36.3%
- 2017$11.5B+259.0%
- 2016$3.2B-59.5%
- 2015$7.91B+9.7%
- 2014$7.2B+82.0%
- 2013$3.96B+331.3%
- 2012$918M+165.5%
- 2011$346M-16.6%
- 2010$415M-43.5%
- 2009$734M-27.8%
- 2008$1.02B-9.6%
- 2007$1.12B+64.7%
- 2006$682M+132.7%
- 2005$293M+230.3%
- 2004$88.8M—
Market Cap values are taken from Alnylam Pharmaceuticals's reported income statements (share counts) and end-of-day prices (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Market Cap at Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's latest reported market cap is $45.7B. Market capitalization is the total dollar value of all outstanding shares — shares outstanding × stock price — and the standard measure of a company's equity value. On this page, historical market cap snaps filing-period share counts to closing prices on or before each statement date (not intraday tick data).
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2026 fiscal year, Alnylam Pharmaceuticals (ALNY) reported market cap of $39.6B – declined 26.0% year-over-year.
Alnylam Pharmaceuticals market cap compound annual growth for the 2021–2026 (5 years) window is +14.6%, with mixed annual results across the window.
Alnylam Pharmaceuticals market cap declined from $53.6B in 2025 to $39.6B in 2026, a 26.0% drawdown.
The record annual market cap stands at $53.6B, reached in 2025; the historical low of $88.8M was recorded in 2004.
Alnylam Pharmaceuticals Market Cap by Year
Alnylam Pharmaceuticals Market Cap 2026: $39.6B
In 2026, Alnylam Pharmaceuticals reported market cap of $39.6B, declined 26.0% below 2025.
Alnylam Pharmaceuticals Market Cap 2025: $53.6B
Alnylam Pharmaceuticals market cap in 2025 was $53.6B, surged 78.3% from 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Market Cap 2024: $30B
2024's market cap for Alnylam Pharmaceuticals came in at $30B, grew 25.6% from 2023.
Alnylam Pharmaceuticals Market Cap 2023: $23.9B
Alnylam Pharmaceuticals posted market cap of $23.9B in 2023, declined 17.3% below 2022.
Alnylam Pharmaceuticals Market Cap 2022: $28.9B
Alnylam Pharmaceuticals market cap in 2022 was $28.9B.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers by Market Cap
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest market cap
| $1.14T | |
| $640B | |
| $466B | |
| $382B | |
| $322B | |
| $229B | |
| $214B | |
| $209B |
- $1.14T
- $466B
- $322B
- $229B
- $209B
Frequently asked questions
Test yourself on ALNY
Market Cap — 10 rounds, every one of them ALNY against another company. Leave whenever you like.
Practice run — it doesn’t move your skill rating and doesn’t touch the leaderboards. Misses do go into your review queue.
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.